Christian Austermann, Robert Schierwagen, Raphael Mohr, Evrim Anadol, Sabine Klein, Alessandra Pohlmann, Christian Jansen, Christian P. Strassburg, Carolynne Schwarze‐Zander, Christoph Boesecke, Jürgen K. Rockstroh, Margarete Odenthal, Jonel Trebicka – 27 February 2017 – Nonalcoholic fatty liver disease contributes to liver‐related mortality and has a high prevalence among patients with human immunodeficiency virus (HIV). The early detection of steatosis could prevent disease progression through life‐style changes.

Jasmohan S. Bajaj, Andrew Fagan, Masoumeh Sikaroodi, Melanie B. White, Richard K. Sterling, HoChong Gilles, Douglas Heuman, Richard T. Stravitz, Scott C. Matherly, Mohammed S. Siddiqui, Puneet Puri, Arun J. Sanyal, Velimir Luketic, Binu John, Michael Fuchs, Vishwadeep Ahluwalia, Patrick M. Gillevet – 27 February 2017 – Liver transplantation (LT) improves daily function and cognition in patients with cirrhosis, but a subset of patients can remain impaired.

Norio Akuta, Chizuru Watanabe, Yusuke Kawamura, Yasuji Arase, Satoshi Saitoh, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Kenji Ikeda, Hiromitsu Kumada – 27 February 2017 – A prospective study based on serial liver biopsies was performed to investigate the efficacy of sodium‐glucose cotransporter 2 inhibitor for nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus. Conclusion: Treatment for 24 weeks resulted in improvement in histopathologic features in all 5 patients.

Hazel Marecki, Adel Bozorgzadeh, Robert J. Porte, Henri G. Leuvenink, Korkut Uygun, Paulo N. Martins – 27 February 2017 – Ex vivo machine perfusion (MP) is a promising way to better preserve livers prior to transplantation. Currently, no methodology has a verified benefit over simple cold storage. Before becoming clinically feasible, MP requires validation in models that reliably predict human performance. Such a model has been found in porcine liver, whose physiological, anatomical, and immunological characteristics closely resemble the human liver.

Amy Tan, Sander S. Florman, Thomas D. Schiano – 27 February 2017 – It is well recognized that solid organ transplantation can transmit bacterial infection and chronic viral hepatitis as well as certain cancers. As indications for liver transplantation (LT) have expanded, it has been used to treat and even cure certain genetic cholestatic disorders, urea cycle defects, and coagulation abnormalities; many of these conditions are potentially transmissible with LT as well.

Gyongyi Szabo – 27 February 2017

Sezai Yilmaz, Cuneyt Kayaalp, Burak Isik, Veysel Ersan, Emrah Otan, Sami Akbulut, Abuzer Dirican, Ramazan Kutlu, Aysegul Sagir Kahraman, Cengiz Ara, Mehmet Yilmaz, Bulent Unal, Cemalettin Aydin, Turgut Piskin, Dincer Ozgor, Mustafa Ates, Fatih Ozdemir, Volkan Ince, Cemalettin Koc, Adil Baskiran, Sait Murat Dogan, Bora Barut, Fatih Sumer, Serdar Karakas, Koray Kutluturk, Saim Yologlu, Harika Gozukara – 27 February 2017 – Reconstruction of anomalous portal vein branching (APVB) during right lobe living donor liver transplantation (LDLT) can be challenging.

Aude Merdrignac, Heithem Jeddou, Pauline Houssel‐Debry, Erwan Flecher, Michel Rayar, Karim Boudjema – 27 February 2017

Luis C. Bertot, Gary P. Jeffrey, Michael Wallace, Gerry MacQuillan, George Garas, Helena L. Ching, Leon A. Adams – 27 February 2017 – Determination of cirrhosis in nonalcoholic fatty liver disease (NAFLD) is important as it alters prognosis and management. We aimed to examine whether cirrhosis was diagnosed incidentally or intentionally in patients with NAFLD.

Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus – 27 February 2017 – Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus–infected individuals receiving direct‐acting antiviral (DAA) therapy. The overall risk among patients with current or prior HBV infection in the context of DAA treatment is unknown. The aim of this evaluation was to identify and characterize HBV reactivation among veterans treated with oral DAA therapy. This retrospective evaluation included 62,290 hepatitis C virus–infected veterans completing oral DAA treatment.